Artiva Biotherapeutics
Clinical-stage biotechnology company developing allogeneic natural killer (NK) cell therapies for the treatment of cancer, leveraging cord blood-derived NK cells.
Notes
Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing allogeneic natural killer (NK) cell therapies for cancer treatment. The company's proprietary platform uses cord blood-derived NK cells to create off-the-shelf cell therapies that can be manufactured at scale and administered to patients without the need for personalized manufacturing.
Artiva's lead program, AB-101, is an allogeneic NK cell therapy being developed for hematologic malignancies and solid tumors. The company's approach leverages the natural tumor-killing capabilities of NK cells while engineering them for enhanced persistence, targeting, and efficacy.
The company went public in July 2024, trading on NASDAQ under the ticker symbol ARTV. Artiva is backed by leading healthcare investors including 5AM Ventures.
Team
- Scott Forrest - Chief Executive Officer
- LinkedIn: linkedin.com/in/scott-forrest
- Hans Klingemann, M.D., Ph.D. - Founder & Chief Scientific Officer
- Shelly Heimfeld, Ph.D. - Co-founder
Additional Research Findings
- NASDAQ listed company (ARTV)
- IPO in July 2024
- Lead program AB-101 allogeneic NK cell therapy
- Cord blood-derived NK cell platform
- Investor: 5AM Ventures
- Focus on allogeneic (off-the-shelf) cell therapy
- San Diego, California headquarters
- Founded 2019
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| 5AM Ventures | Menlo Park, USA | biotech-focused | seedseries-a+1 | 8 |